(LXRX) Lexicon Pharmaceuticals - Overview
Stock: Sotagliflozin, LX9211, LX9851
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 111% |
| Relative Tail Risk | -14.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.05 |
| Alpha | 50.67 |
| Character TTM | |
|---|---|
| Beta | 0.847 |
| Beta Downside | 0.816 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.83% |
| CAGR/Max DD | -0.20 |
Description: LXRX Lexicon Pharmaceuticals December 29, 2025
Lexicon Pharmaceuticals (NASDAQ:LXRX) is a U.S.-based biotech that develops oral small-molecule therapies. Its lead asset, sotagliflozin, is an SGLT-1/2 inhibitor approved for reducing cardiovascular death, heart-failure hospitalizations, and urgent visits in patients with heart failure, type 2 diabetes, or chronic kidney disease. The pipeline includes sotagliflozin in Phase 3 for hypertrophic cardiomyopathy and type 1 diabetes, LX9211 (Phase II completed for neuropathic pain), and LX9851 (obesity and cardiometabolic risk). The company partners with Viatris and Bristol-Myers Squibb for commercialization and co-development.
Key metrics (as of the latest 10-Q): market capitalization ≈ $1.2 B, cash and equivalents ≈ $350 M, giving ~12-month runway at current burn (~$30 M/quarter). The SGLT-inhibitor class is projected to grow > 10 % CAGR through 2028, driven by expanding indications beyond diabetes. Lexicon’s upcoming catalysts are the Phase 3 readout for HCM (Q3 2025) and potential FDA action on its obesity candidate LX9851, which could tap the $70 B global obesity-treatment market.
For a data-driven assessment of how Lexicon’s valuation stacks up against sector peers, you might find ValueRay’s analyst tools useful.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -68.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.35 > 0.02 and ΔFCF/TA 29.65 > 1.0 |
| NWC/Revenue: 142.3% < 20% (prev 4448 %; Δ -4305 % < -1%) |
| CFO/TA -0.35 > 3% & CFO -72.1m > Net Income -68.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (363.4m) vs 12m ago 0.53% < -2% |
| Gross Margin: 63.05% > 18% (prev -1.92%; Δ 6497 % > 0.5%) |
| Asset Turnover: 26.89% > 50% (prev 1.63%; Δ 25.26% > 0%) |
| Interest Coverage Ratio: -4.81 > 6 (EBITDA TTM -48.3m / Interest Expense TTM 10.2m) |
Altman Z'' -15.00
| A: 0.49 (Total Current Assets 122.5m - Total Current Liabilities 21.7m) / Total Assets 205.9m |
| B: -9.72 (Retained Earnings -2.00b / Total Assets 205.9m) |
| C: -0.19 (EBIT TTM -48.9m / Avg Total Assets 263.5m) |
| D: -23.34 (Book Value of Equity -2.00b / Total Liabilities 85.8m) |
| Altman-Z'' Score: -54.24 = D |
Beneish M 1.00
| DSRI: 0.06 (Receivables 2.33m/2.90m, Revenue 70.9m/5.23m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 2.54 (AQ_t 0.36 / AQ_t-1 0.14) |
| SGI: 13.55 (Revenue 70.9m / 5.23m) |
| TATA: 0.02 (NI -68.6m - CFO -72.1m) / TA 205.9m) |
| Beneish M-Score: 6.13 (Cap -4..+1) = D |
What is the price of LXRX shares?
Over the past week, the price has changed by +6.03%, over one month by +7.89%, over three months by -13.99% and over the past year by +66.22%.
Is LXRX a buy, sell or hold?
- StrongBuy: 1
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LXRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 2.9 | 137.4% |
| Analysts Target Price | 2.9 | 137.4% |
| ValueRay Target Price | 1.1 | -8.1% |
LXRX Fundamental Data Overview February 03, 2026
P/B = 3.4786
P/EG = -0.14
Revenue TTM = 70.9m USD
EBIT TTM = -48.9m USD
EBITDA TTM = -48.3m USD
Long Term Debt = 56.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.64m USD (from shortTermDebt, last quarter)
Debt = 58.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.49m USD (from netDebt column, last quarter)
Enterprise Value = 363.8m USD (421.6m + Debt 58.1m - CCE 116.0m)
Interest Coverage Ratio = -4.81 (Ebit TTM -48.9m / Interest Expense TTM 10.2m)
EV/FCF = -5.01x (Enterprise Value 363.8m / FCF TTM -72.6m)
FCF Yield = -19.95% (FCF TTM -72.6m / Enterprise Value 363.8m)
FCF Margin = -102.4% (FCF TTM -72.6m / Revenue TTM 70.9m)
Net Margin = -96.77% (Net Income TTM -68.6m / Revenue TTM 70.9m)
Gross Margin = 63.05% ((Revenue TTM 70.9m - Cost of Revenue TTM 26.2m) / Revenue TTM)
Gross Margin QoQ = 99.93% (prev 99.28%)
Tobins Q-Ratio = 1.77 (Enterprise Value 363.8m / Total Assets 205.9m)
Interest Expense / Debt = 3.71% (Interest Expense 2.15m / Debt 58.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -38.7m (EBIT -48.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.64 (Total Current Assets 122.5m / Total Current Liabilities 21.7m)
Debt / Equity = 0.48 (Debt 58.1m / totalStockholderEquity, last quarter 120.2m)
Debt / EBITDA = -0.18 (negative EBITDA) (Net Debt 8.49m / EBITDA -48.3m)
Debt / FCF = -0.12 (negative FCF - burning cash) (Net Debt 8.49m / FCF TTM -72.6m)
Total Stockholder Equity = 129.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.02% (Net Income -68.6m / Total Assets 205.9m)
RoE = -52.90% (Net Income TTM -68.6m / Total Stockholder Equity 129.6m)
RoCE = -26.29% (EBIT -48.9m / Capital Employed (Equity 129.6m + L.T.Debt 56.5m))
RoIC = -18.58% (negative operating profit) (NOPAT -38.7m / Invested Capital 208.0m)
WACC = 8.30% (E(421.6m)/V(479.8m) * Re(9.04%) + D(58.1m)/V(479.8m) * Rd(3.71%) * (1-Tc(0.21)))
Discount Rate = 9.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 21.81%
Fair Price DCF = unknown (Cash Flow -72.6m)
EPS Correlation: 68.11 | EPS CAGR: 35.28% | SUE: 1.93 | # QB: 1
Revenue Correlation: 93.42 | Revenue CAGR: 533.1% | SUE: 0.90 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.07 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.25 | Chg30d=+0.013 | Revisions Net=+1 | Growth EPS=-47.7% | Growth Revenue=-55.8%